Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $32.6 million.

  • TScan Therapeutics' Cash from Investing Activities rose 13955.65% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.8 million, marking a year-over-year increase of 25621.4%. This contributed to the annual value of -$52.6 million for FY2024, which is 1340.71% up from last year.
  • As of Q3 2025, TScan Therapeutics' Cash from Investing Activities stood at $32.6 million, which was up 13955.65% from $48.4 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Cash from Investing Activities high stood at $48.4 million for Q2 2025, and its period low was -$82.4 million during Q3 2024.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$838000.0 (2023), whereas its average is -$1.7 million.
  • In the last 5 years, TScan Therapeutics' Cash from Investing Activities tumbled by 1438443.4% in 2023 and then skyrocketed by 441539.38% in 2024.
  • Over the past 5 years, TScan Therapeutics' Cash from Investing Activities (Quarter) stood at -$2.2 million in 2021, then skyrocketed by 37.72% to -$1.4 million in 2022, then surged by 238.93% to $1.9 million in 2023, then skyrocketed by 1326.71% to $27.3 million in 2024, then increased by 19.36% to $32.6 million in 2025.
  • Its Cash from Investing Activities was $32.6 million in Q3 2025, compared to $48.4 million in Q2 2025 and $13.5 million in Q1 2025.